Literature DB >> 23267148

ROS mediate proapoptotic and antisurvival activity of oleanane triterpenoid CDDO-Me in ovarian cancer cells.

Xiaohua Gao1, Yongbo Liu, Dorrah Deeb, Patricia Liu, Annie Liu, Ali S Arbab, Subhash C Gautam.   

Abstract

Oleanane triterpenoids are broad-spectrum antiproliferative and proapoptotic agents. In this study, we investigated whether reactive oxygen species (ROS) play a role in the antitumor activity of methyl-2-cyano-3, 12-dioxooleana-1, 9(11)-dien-28-oate (CDDO-Me) in OVCAR-5 and MDAH 2774 ovarian cancer cells. Treatment with CDDO-Me caused the generation of ROS (H(2)O(2)) and pre-treatment with N-acetylcysteine (NAC) prevented the generation of ROS. NAC also blocked the inhibition of cell proliferation by CDDO-Me. Likewise, NAC prevented the CDDO-Me-caused binding of fluorescein isothiocyanate (FITC)-tagged annexin V, cleavage of poly ADP-ribose polymerase-1 (PARP-1), procaspases-3, -8 and -9 and loss of mitochondrial membrane potential. CDDO-Me inhibited the expression of prosurvival phospho-AKT (p-AKT), phospho-mammalian target of rapamycin (p-mTOR) and nuclear factor-kappa B (NF-κB) (p65) signaling molecules and NF-κB-regulated antiapoptotic B-cell lymphoma-2 (BCL-2), B-cell lymphoma-extra large (BCL-xL), cellular inhibitor of apoptosis protein 1(c-IAP1) and survivin, but pre-treatment with NAC blocked the down-modulation of these signaling and antiapoptotic proteins by CDDO-Me. Together, these results indicate the pivotal role ROS play in the antiproliferative- and apoptosis-inducing activity of CDDO-Me in ovarian cancer cells; however, the role of ROS in the down-regulation of prosurvival AKT, mTOR, NF-κB and antiapoptotic BCL-2, BCL-xL, c-IAP1 and survivin warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23267148      PMCID: PMC3711076     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  21 in total

Review 1.  The TOR pathway: a target for cancer therapy.

Authors:  Mary-Ann Bjornsti; Peter J Houghton
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

2.  Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.

Authors:  S R Datta; H Dudek; X Tao; S Masters; H Fu; Y Gotoh; M E Greenberg
Journal:  Cell       Date:  1997-10-17       Impact factor: 41.582

Review 3.  First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?

Authors:  A du Bois; J P Neijt; J T Thigpen
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

Review 4.  The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance.

Authors:  M W Mayo; A S Baldwin
Journal:  Biochim Biophys Acta       Date:  2000-03-27

5.  Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

Authors:  J P Neijt; S A Engelholm; M K Tuxen; P G Sorensen; M Hansen; C Sessa; C A de Swart; F R Hirsch; B Lund; H C van Houwelingen
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

Review 6.  Superoxide and hydrogen peroxide in relation to mammalian cell proliferation.

Authors:  R H Burdon
Journal:  Free Radic Biol Med       Date:  1995-04       Impact factor: 7.376

Review 7.  Redox signaling and the MAP kinase pathways.

Authors:  Martine Torres; Henry Jay Forman
Journal:  Biofactors       Date:  2003       Impact factor: 6.113

Review 8.  Cellular response to oxidative stress: signaling for suicide and survival.

Authors:  Jennifer L Martindale; Nikki J Holbrook
Journal:  J Cell Physiol       Date:  2002-07       Impact factor: 6.384

9.  Inhibition of the tumor-promoting action of 12-O-tetradecanoylphorbol-13-acetate by some oleanane-type triterpenoid compounds.

Authors:  H Nishino; A Nishino; J Takayasu; T Hasegawa; A Iwashima; K Hirabayashi; S Iwata; S Shibata
Journal:  Cancer Res       Date:  1988-09-15       Impact factor: 12.701

Review 10.  Cell respiration and formation of reactive oxygen species: facts and artefacts.

Authors:  H Nohl; A V Kozlov; L Gille; K Staniek
Journal:  Biochem Soc Trans       Date:  2003-12       Impact factor: 5.407

View more
  17 in total

1.  The role of natural products in revealing NRF2 function.

Authors:  Donna D Zhang; Eli Chapman
Journal:  Nat Prod Rep       Date:  2020-05-13       Impact factor: 13.423

Review 2.  Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence.

Authors:  Muthu K Shanmugam; Xiaoyun Dai; Alan Prem Kumar; Benny K H Tan; Gautam Sethi; Anupam Bishayee
Journal:  Cancer Lett       Date:  2014-01-30       Impact factor: 8.679

3.  Protection of HepG2 cells against acrolein toxicity by 2-cyano-3,12-dioxooleana-1,9-dien-28-imidazolide via glutathione-mediated mechanism.

Authors:  Halley Shah; Adam M Speen; Christina Saunders; Elizabeth A S Brooke; Palanisamy Nallasamy; Hong Zhu; Y Robert Li; Zhenquan Jia
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-11

4.  Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma.

Authors:  Yan Zhao; Meirong Huo; Zhenghong Xu; Yuhua Wang; Leaf Huang
Journal:  Biomaterials       Date:  2015-08-01       Impact factor: 12.479

5.  Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells.

Authors:  Yan-Yang Wang; Yin-Xue Yang; Ren Zhao; Shu-Ting Pan; Hong Zhe; Zhi-Xu He; Wei Duan; Xueji Zhang; Tianxin Yang; Jia-Xuan Qiu; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-02-17       Impact factor: 4.162

Review 6.  Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.

Authors:  Yan-Yang Wang; Yin-Xue Yang; Hong Zhe; Zhi-Xu He; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2014-10-23       Impact factor: 4.162

7.  A Natural Combination Extract of Viscum album L. Containing Both Triterpene Acids and Lectins Is Highly Effective against AML In Vivo.

Authors:  Catharina I Delebinski; Monika Twardziok; Susann Kleinsimon; Florian Hoff; Katharina Mulsow; Jana Rolff; Sebastian Jäger; Angelika Eggert; Georg Seifert
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

Review 8.  Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment.

Authors:  Yan-Yang Wang; Hong Zhe; Ren Zhao
Journal:  Mol Cancer       Date:  2014-02-20       Impact factor: 27.401

9.  Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells.

Authors:  Zhi-Wei Zhou; Xing-Xiao Li; Zhi-Xu He; Shu-Ting Pan; Yinxue Yang; Xueji Zhang; Kevin Chow; Tianxin Yang; Jia-Xuan Qiu; Qingyu Zhou; Jun Tan; Dong Wang; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-03-12       Impact factor: 4.319

10.  Ca2+ influx-mediated dilation of the endoplasmic reticulum and c-FLIPL downregulation trigger CDDO-Me-induced apoptosis in breast cancer cells.

Authors:  Soo Ah Jeong; In Young Kim; A Reum Lee; Mi Jin Yoon; Hyeseong Cho; Jong-Soo Lee; Kyeong Sook Choi
Journal:  Oncotarget       Date:  2015-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.